FIELD: biotechnology.
SUBSTANCE: following is presented: an antibody that specifically binds to guanylate cyclase C (GUCY2c), bispecific antibodies that specifically bind to GUCY2c and CD3, methods of treating GUCY2c-related diseases in a patient, nucleic acid molecules, expression vectors containing a polynucleotide, host cells for obtaining antibodies and compositions for the treatment of diseases associated with GUCY2c. The methods of producing the antibody and bispecific antibody are also disclosed.
EFFECT: obtaining new antibodies with high affinity for GUCY2 and CD3.
36 cl, 38 dwg, 49 tbl, 35 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| VARIANT CD3 BINDING DOMAINS AND THEIR USE IN COMBINATION THERAPY FOR TREATMENT OF DISEASES | 2019 |
|
RU2810222C2 |
| MULTIMERIZATION TECHNOLOGIES | 2014 |
|
RU2714733C2 |
| CD3-BINDING DOMAIN | 2015 |
|
RU2742691C2 |
| MANAGEMENT, NAVIGATION AND CONTROL PROTEINS AND METHOD OF THEIR OBTAINING AND USE | 2019 |
|
RU2811457C2 |
| TRISPECIFIC BINDING PROTEINS, RELATED METHODS AND VERSIONS OF USE THEREOF | 2020 |
|
RU2822200C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2022 |
|
RU2824285C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
